GlassScriptPhysician profile
Archana Barry
NPI 1609878545
$4,354.84
in general payments reported to CMS, 2019-2025
26 companies · $627 in 2025
The $627 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $101 · 2021: $317 · 2022: $1,620 · 2023: $1,072 · 2024: $363 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,062.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,062.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $621.99 | 2021-2023 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $421.38 | 2022-2025 | Caplyta |
| Alkermes, INC. | $357.34 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Vanda Pharmaceuticals INC. | $342.59 | 2019-2023 | Hetlioz, Fanapt |
| Abbvie INC. | $310.06 | 2022-2025 | Vraylar |
| Corium, LLC | $248.33 | 2022-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $235.48 | 2019-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $225.75 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $219.23 | 2020-2024 | Jornay Pm |
| Tris Pharma INC | $208.97 | 2022-2025 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $194.85 | 2022-2025 | Uzedy, Austedo, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $191.07 | 2019-2025 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $186.97 | 2022-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Lundbeck LLC | $123.00 | 2019-2025 | Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $106.60 | 2021-2023 | Trintellix |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $92.81 | 2025 | Cobenfy |
| Axsome Therapeutics, INC. | $70.20 | 2022-2023 | Auvelity |
| Indivior INC. | $38.86 | 2019-2023 | Perseris |
| Idorsia Pharmaceuticals US INC | $30.71 | 2023 | Quviviq |
| Noven Therapeutics, LLC | $30.03 | 2022 | |
| Almatica Pharma LLC | $23.04 | 2022 | |
| Neos Therapeutics, LP | $20.83 | 2019 | |
| Adlon Therapeutics L.P. | $15.19 | 2021 | |
| Eisai INC. | $13.83 | 2021 | |
| Collegium Pharmaceutical, INC. | $13.65 | 2025 | Jornay Pm |
| Shire North American Group INC | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Archana Barry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.